A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Nasal polyps; Rhinosinusitis
Focus Registrational; Therapeutic Use
Acronyms ORCHID
Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca KK

Most Recent Events

31 Aug 2023 Planned primary completion date changed from 13 Sep 2024 to 19 Aug 2024.
25 May 2023 Status changed from recruiting to active, no longer recruiting.
21 Feb 2023 Planned End Date changed from 8 Sep 2025 to 10 Oct 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight